|drug445||Biological data Wiki||0.50|
|drug784||Clinical data Wiki||0.41|
|drug3775||cardiac magnetic resonance Wiki||0.35|
|drug4136||viral sequence Wiki||0.35|
|drug2444||Percutaneous Coronary Revascularization for STEMI Wiki||0.35|
|drug3988||oropharyngeal and intestinal microbiota Wiki||0.35|
|drug3727||albuterol sulfate (nebulizer) Wiki||0.35|
|drug3240||Storage of operating waste Wiki||0.35|
|drug3726||albuterol sulfate (MDI) Wiki||0.35|
|drug3867||host immune factors Wiki||0.35|
|drug3866||host genotype Wiki||0.35|
|drug2215||No intervention Wiki||0.07|
|D009203||Myocardial Ischemia NIH||0.82|
|D016757||Death, Sudden, Cardiac NIH||0.35|
|D017180||Tachycardia, Ventricular NIH||0.35|
|D000072657||ST Elevation Myocardial Infarction NIH||0.25|
|D016769||Embolism and Thrombosis NIH||0.18|
|D011655||Pulmonary Embolism NIH||0.09|
|HP:0001658||Myocardial infarction HPO||0.82|
|HP:0004756||Ventricular tachycardia HPO||0.35|
There are 8 clinical trials
In late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.
Description: Free wall rupture, acute ischemic mitral regurgitation, ventricular septal ruptureMeasure: The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI) Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )
Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020Measure: Rates of patients presenting with acute myocardial infarction Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )
Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19Measure: Patient profile during admission for acute myocardial infarction Time: 3 months (between March 1 to May 31
Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19Measure: Medical care times analysis Time: 3 months (between March 1 to May 31)
Description: Delay in minutes from symptom onset and STEMI (ST Segment Elevation Myocardial Infarction) diagnosis; and delay in minutes from onset of symptoms and primary PCI (percutaneous coronary intervention)Measure: Medical care times analysis Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )
Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at dischargeMeasure: Clinical evolution of patients Time: 3 months (between March 1 to May 31)
Description: Number of in hospital outcomes including orotracheal intubation, cardiogenic shock, arrhythmias (ventricular tachycardia of ventricular fibrillation) and in hospital cardiac arrestMeasure: Clinical evolution of patients Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )
Description: Number of patient admitted in cardiology department with STEMI (ST Segment Elevation Myocardial Infarction)Measure: STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )
Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19Measure: Proportion of patients who underwent systemic thrombolysis Time: 3 months (between March 1 to May 31)
Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19Measure: Proportion of patients infected with COVID-19 Time: 3 months (between March 1 to May 31)
The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.
Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.Measure: Acute cardiovascular event triggered by COVID-19 stress Time: 4 months
Description: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.Measure: Ventricular tachycardia Time: 4 months
Description: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonanceMeasure: acute stroke Time: 4 months
Description: Finding an episode of ventricular tachycardia on interrogation of ICD tracingMeasure: Implantable cardioverter defibrillator (ICD) shock Time: 4 months
The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
Description: Number of patients undergoing primary angioplastyMeasure: Number of patients undergoing primary angioplasty Time: March April 2019 and 2020
Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset; Time: March April 2019 and 2020
Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admissionMeasure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission Time: March April 2019 and 2020
Description: In-Hospital mortalityMeasure: In-hospital mortality Time: March April 2019 and 2020
Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.
Description: Myocardtitis diagnosis in patients COVID+ and troponin+Measure: characterize the myocardial damage associated with CoV-2 SARS infection Time: Through study completion, an average of 1 year
The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.
Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. [Epub ahead of print] and Tang N, et al. Thromb. Haemost. 2020 Feb 19. [EPub Ahead of Print]). Abnormal coagulation testing results, especially markedly elevated D-dimer and FDP, have been associated with a poor prognosis in COVID-19 infection. We propose the following Electronic Health Record (EHR)-guided 10000-patient, retrospective observational cohort study to assess VTE incidence, risk factors, prevention and management patterns, and thrombotic outcomes in patients with COVID-19 infection. In order to gain the valuable perspective of other regional and national centers providing care for large populations of COVID-19, we have started a collaborative network with 5 additional sites which will provide us with de-identified data from 1000 patients each. These 5000 patients in addition to the 5000-patient cohort we are enrolling within the Mass General Brigham Network will comprise this study population.
Description: Frequency (%) of arterial or venous thromboembolismMeasure: Frequency of arterial or venous thromboembolism over 30 days Time: 30 days
Description: Frequency (%) of arterial or venous thromboembolismMeasure: Frequency of arterial or venous thromboembolism over 90 days Time: 90 days
Description: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomesMeasure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 30 days Time: 30 days
Description: Frequency (%) of all-cause death, bleeding, and thromboembolic outcomesMeasure: Frequency of all-cause death, bleeding, and thromboembolic outcomes at 90 days Time: 90 days
The COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.
Description: Daily number of admissions for acute cardio- and neurivascular conditions in France.Measure: Daily number of admissions for acute cardio- and neurivascular conditions in France. Time: 1 day
Description: Specific mortality rate.Measure: Specific mortality rate. Time: 1 day
To compare myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR
Description: Distribution and Extent of myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR.Measure: comparison between COVID-19 and COVID-19 presented with myocardial infarction Time: baseline
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports